Zacks Research Upgrades Nutriband (NASDAQ:NTRB) to Hold

Nutriband (NASDAQ:NTRB) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

NTRB has been the topic of a number of other research reports. Wall Street Zen downgraded Nutriband from a “hold” rating to a “sell” rating in a report on Friday, September 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Nutriband in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $13.00.

Nutriband Stock Performance

NTRB opened at $5.86 on Tuesday. The company has a quick ratio of 4.70, a current ratio of 4.78 and a debt-to-equity ratio of 0.01. The firm has a market cap of $70.53 million, a PE ratio of -2.04 and a beta of 1.54. The business has a fifty day simple moving average of $6.97 and a 200-day simple moving average of $7.06. Nutriband has a fifty-two week low of $3.72 and a fifty-two week high of $11.78.

Nutriband (NASDAQ:NTRB) last posted its quarterly earnings data on Tuesday, September 9th. The company reported ($2.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.95). The firm had revenue of $0.62 million during the quarter, compared to analyst estimates of $0.71 million. Nutriband had a negative return on equity of 85.40% and a negative net margin of 398.29%. As a group, equities analysts predict that Nutriband will post -0.6 EPS for the current fiscal year.

Institutional Trading of Nutriband

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE acquired a new position in shares of Nutriband during the first quarter worth approximately $29,000. Consolidated Portfolio Review Corp bought a new stake in shares of Nutriband in the second quarter valued at approximately $81,000. Finally, Vanguard Group Inc. grew its stake in shares of Nutriband by 1.6% in the third quarter. Vanguard Group Inc. now owns 202,738 shares of the company’s stock worth $1,429,000 after acquiring an additional 3,111 shares during the last quarter. Institutional investors and hedge funds own 19.70% of the company’s stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.